Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 2,083 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Open Label Extension Study Clear all

Conditions: HIV-1 Infection
Interventions: Teropavimab, Zinlirvimab, Lenacapavir Tablet, Lenacapavir Injection, Antiretroviral Therapy; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 29
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 25 more

Conditions: Atopic Dermatitis Eczema
Interventions: AO+Mist, Placebo; Other
Lead sponsor: AOBiome LLC; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Parkinson's Disease
Interventions: Prasinezumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 53
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 47 more

Conditions: Familial Partial Lipodystrophy
Interventions: volanesorsen, Placebo; Drug
Lead sponsor: Akcea Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 6
States / cities: Ann Arbor, Michigan • Rochester, Minnesota • St Louis, Missouri + 3 more

Conditions: Healthy Volunteers
Interventions: Febuxostat XR, Maalox Advance Regular Strength liquid; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: Albiglutide, Auto-injector; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Not listed
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 27
States / cities: Phoenix, Arizona • Fresno, California • Lomita, California + 22 more

Conditions: Huntington's Disease (HD)
Interventions: Creatine monohydrate; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Macular Telangiectasia Type 2 (MacTel)
Interventions: NT-501/revakinagene taroretcel-lwey; Combination Product
Lead sponsor: Neurotech Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 23
States / cities: La Jolla, California • Los Angeles, California • Palo Alto, California + 19 more

Conditions: Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases
Interventions: Golimumab 50 mg SC, Golimumab 2 mg/kg IV, Methotrexate (MTX), Placebo SC, Placebo IV; Drug
Lead sponsor: Janssen Biotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 89
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 86 more

Conditions: Pseudohypoparathyroidism, Pseudohypoparathyroidism Type 1a, Albright Hereditary Osteodystrophy
Interventions: Theophylline ER; Drug
Lead sponsor: Jaclyn Tamaroff; Other
Eligibility: 2 Years to 99 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hyperlipidemia
Interventions: Evacetrapib, Atorvastatin, Ezetimibe, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 61
States / cities: Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 56 more

Conditions: Acidosis, Renal Tubular
Interventions: ADV7103; Drug
Lead sponsor: Advicenne Pharma; Industry
Eligibility: 4 Months to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
Interventions: Guselkumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 3 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 6
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Cincinnati, Ohio + 2 more

Conditions: Pharmacokinetics of ASP015K, Food Effect, Healthy Volunteers
Interventions: ASP015K ER, ASP015K IR; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Gouty Arthritis
Interventions: Canakinumab 150mg in prefilled syringe; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 54
States / cities: Anniston, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 50 more

Conditions: Phenylketonurias
Interventions: sapropterin dihydrochloride; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 8 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 14
States / cities: Los Angeles, California • Oakland, California • Sacramento, California + 11 more

Conditions: Healthy
Interventions: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Polycystic Kidney, Autosomal Dominant
Interventions: Tolvaptan; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 11
States / cities: Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 8 more

Conditions: Dry Age-related Macular Degeneration
Interventions: Valeda Light Delivery System; Device
Lead sponsor: LumiThera, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Beverly Hills, California • Palo Alto, California • Altamonte Springs, Florida + 4 more

Conditions: Osteoarthritis of the Knee
Interventions: FX006 10 mg, FX006 40 mg, TCA IR 40 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Paducah, Kentucky • Duncansville, Pennsylvania • Dallas, Texas

Conditions: Multiple Sclerosis
Interventions: IPX056 20 mg, IPX056 40 mg, Encapsulated Baclofen 20 mg, Placebo Baclofen Tablet, IPX056 10 mg, IPX056 30 mg, IPX056 35 mg, Placebo IPX056 20 mg, Placebo IPX056 40 mg; Drug
Lead sponsor: Impax Laboratories, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 20
States / cities: Tucson, Arizona • Little Rock, Arkansas • Colorado Springs, Colorado + 16 more

Conditions: Hypertension, Pulmonary
Interventions: current marketed FLOLAN (epoprostenol sodium), new thermo stable formulation of epoprostenol sodium; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Miami Beach, Florida • Chicago, Illinois • Baltimore, Maryland + 3 more

Conditions: Bipolar I Disorder, Manic or Mixed
Interventions: divalproex sodium; Drug
Lead sponsor: Abbott; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: North Chicago, Illinois

Conditions: Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
Interventions: AR882 Dose 1, AR882 Dose 2, Allopurinol Tablet; Drug
Lead sponsor: Arthrosi Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 7 more

Search by objective public record fields.

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

Cosmetic Study to Improve the Appearance of Skin Afflicted With Mild to Moderate Atopic Dermatitis.

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy

Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule

Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects

Creatine Safety & Tolerability in Huntington's Disease

Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants

Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)

Theophylline for Treatment of Pseudohypoparathyroidism

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol

Extension Study in Primary Distal Renal Tubular Acidosis

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K

Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)

Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee

IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis

Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)

Evaluate the Safety of Depakote Extended Release Tablets in the Treatment of Mania Associated With Bipolar Disorder in Children and Adolescents

Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout